EVGN
Evogene Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.50
−0.85%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.50
From 52W high−65.82%
Volume17873.00
Market cap$7.88M
P/E (TTM)—
P/S (TTM)6.0x
Div yield—
Key dataSep 18, 2026
Open
$0.50
From 52W high
−65.82%
Volume
17873.00
Market cap
$7.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
40.1
MomentumView details →
1D Return
−0.85%
YTD Return
−57.07%
SummaryUpdated Jun 1, 2026
Evogene Ltd. (NASDAQ:EVGN) is an Israeli computational biology company founded in 1999 and headquartered in Rehovot, Israel. The company went public in 2010 and operates as a technology-driven life sciences platform that uses artificial intelligence and big data to discover and develop products across agriculture, human health, and industrial applications. Evogene has evolved from a traditional biotechnology company into a computational biology pioneer, leveraging its proprietary Computational Predictive Biology (CPB) platform to create multiple subsidiary companies targeting specific market segments.
Similar companies
Latest newsMore news →
Evogene Ltd. responded to dissident shareholders, urging shareholders to vote for its nominees at the upcoming Annual General Meeting on September 4, 2026.20d agoEvogene Ltd. reported its financial results for the second quarter and first half of 2026, with a net loss of approximately $1.8 million in Q2 2026, compared to $4.7 million in Q2 2025.33d ago